Ask AI
ProCE Banner Activity

VMAT2 Inhibitors in Geriatric and Complex Populations: Mechanistic Insights, Formulation Advances, and Age-Appropriate Dosing Strategies

Slideset

This downloadable slideset explores the molecular pharmacology of VMAT2 inhibitors, comparing agents, including their pharmacokinetic profiles, receptor selectivity, and extended-release formulations designed for dysphagia management. Read expert guidance on age-related metabolic changes impacting drug clearance, and titration protocols for patients with hepatic impairment or polypharmacy, emphasizing fall risk reduction and swallow-safe administration.

Released: December 09, 2025

Continue Activity

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by an educational grant from Neurocrine Biosciences.

Neurocrine Biosciences

Target Audience

This educational activity is intended for psychiatrists, geriatricians, nurse practitioners, physician associates, general and family practice physicians, pharmacists, psychologists, social workers, and other healthcare professionals who treat patients or advise HCP care teams regarding their patients with tardive dyskinesia who may benefit from this education.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Identify risk factors for TD that increase susceptibility in older individuals​

  • Implement best practices for using screening and assessment tools with patients at risk for TD

  • Interpret screening tool results to identify TD, considering patient and caregiver reports

  • Evaluate the safety, effectiveness, and pharmacologic properties of VMAT2 inhibitors for managing TD in older adults and special populations

  • Develop an individualized treatment plan for diverse patient populations with TD